Open Orphan Share Discussion Threads

[12toes] 10/5/2021 08:29

We want some proper news friel - none of this change down the back of the sofa stuff

[troutisout] 10/5/2021 08:17

The important thing about this news is this is for new variant strains and is for Imperial College and Wellcome Trust. Think of the implications.....

More to come, not all Covid related...

[m5] 10/5/2021 08:09

Excellent start to the week.

[malcolmmm] 10/5/2021 07:17

Upward and onward. Shows the government confidence in ORPH many others will follow

[12toes] 10/5/2021 07:16

And friel still hasn't given XD date and any price changing news What a clown

[king kong dong] 10/5/2021 07:13

£3m excellent news for me! Keep's the lights on!

[12toes] 10/5/2021 07:10

A measly 3 million quid We want proper news friel

[lfdkmp] 10/5/2021 07:08

Completes before end 2021.

Should enhance forward looking projections and statements.

[volsung] 10/5/2021 07:05

Sehr gut, ja?

[rivaldo] 10/5/2021 06:53

Excellent news, cheers.....

"Pharma firm Open Orphan to test Covid variants on young adults

An Aim-listed pharmaceutical business has signed a £3 million deal with Imperial College to run the world’s first clinical trials that deliberately infect young adults with Covid-19 variants to test the robustness of existing vaccines.

Open Orphan, through its hVivo subsidiary, will run its clinical trials from a 19-bedroom quarantine clinic in Whitechapel, east London, which opened in February. The business has signed a contract with the government to recruit volunteers for its coronavirus studies through its own recruitment website, UKCovidChallenge.com.

It is understood that volunteers for clinical trials are usually compensated about £4,500 for their time but they will receive about £6,000 to take part, reflecting the multiple checks that will be required for a year after being infected with Covid-19.

Open Orphan will develop a pure version of a Covid strain, for example the Indian, South African or Brazillian variant, and test the effectiveness of current vaccines on the market. It is not clear as yet which of the existing vaccines will be tested as the government has recently said that people aged under 40 will be offered an alternative to the AstraZeneca jab amid greater caution over blood clots and low infection rates. Open Orphan’s subsidiary, hVivo, has two decades of experience in manufacturing viruses, including influenza and the common cold, to test the effect of treatments.

Viruses mutate to survive and spread but a variant that is more infectious and equally dangerous will lead to more deaths. There had originally been concerns that the UK/Kent strain uncovered towards the end of last year was up to 70 per cent more infectious. The South African and Brazilian variants are thought to have a mutation that may help the virus evade antibodies which are needed for the immune system to fight off infection.

The prime minister has said that the Indian variant of coronavirus is “of concern” and Public Health England has put in place surge testing to monitor the spread in areas where the variant has been identified.

The government is considering offering everyone aged 50 and over a booster in the autumn in an attempt to eradicate the threat of Covid-19 by Christmas."

[sh0wmethemoney] 10/5/2021 01:43

Says 3m contract been signed, RNS day hopefully

[pierre oreilly] 09/5/2021 21:44

luke, thanks for your support but as you can see, i don't think investors are wanted on the traders' thread, and vv. I tell them what they don't want to accept - things like 80% of traders lose all their money they deposit with a cfd/sb company (a legal requirement that the company has to disclose to prospective customers). The other influential tool is charting of course, which eases the subtle ramping and deramping, where the same graph can be bullish or bearish depending on the current short or long holding.

Those trading aim shares are, by necessity, bit players. Liquidity ensures that. They have different aims and very low expectations (and even those aren't met in the majority of cases) to investors who reap the real rewards. You'll get every trader saying they make a bomb, and none admitting when they lose, or sell at 7p and the price goes up to 40p quite quickly. (anyone want to volunteer selling at 7p and getting left behind? Thought not. 10p, 20p?). Remember groups of con men have to be your friends, giving you friendly advice to buy as they sell, and sell as they buy, all supported by those magical and mysterious charts of course.

(and btw, when traders have been studied by nobel prize winning economists their performance is random. City traders win by trading opm and taking a cut whether they win or lose).

Cathal is an investor in orph, not a trader. Why would he make that choice?

Anyhow, my next post will be about orph, not telling people what they don't want to hear.

[jigger_1] 09/5/2021 20:24

Vaxart Norovirus vaccine candidate CHIM

[m5] 09/5/2021 20:17

Now that would be nuts!!

[jigger_1] 09/5/2021 20:16

Professor Peter Horby, who set up the UK’s Recovery Trial and is a member of the government’s Scientific Advisory Group for Emergencies (Sage), said more investment is needed to produce medicine capable of treating those infected….

…. It’s expected the UK’s new antiviral taskforce will pump money into this area of research and development, hopefully leading to the emergence of a new generation of drugs which can target both Sars-CoV-2 and the severe symptoms it triggers…

….. In its search for ‘Covid pills’ that the public can take at home, the UK government will likely be forced to test and repurpose those antiviral drugs that are already licensed, according to Professor Stephen Griffin, a virologist at Leeds University.

“If they’re working to autumn, it’s a tight timeline,” he told The Independent. “To do a human trial even before October is going to be pretty quick. We’ve also got the issue that our infection numbers are dwindling. Doing any type of trial in this country will be a challenge.”




Anyone know of a company who is a world leader in accelerating antiviral testing, is already working with the UK Gov and can solve this challenge?

[12toes] 09/5/2021 19:56

No I am not happy, 6 of you cohorts on the other forum have voted down for my friend Pierre to return

[eeza] 09/5/2021 19:07

OO involved?

"The world is one step closer to a vaccine against peanut allergy after UK biotech Allergy Therapeutics announced plans to test its jab in human clinical trials...."

[jeanesy] 09/5/2021 12:04

Has the techinvest article been published this weekend ?

[pgaffney] 09/5/2021 10:51

Thanks Malcolmmm
Is Techinvest worth subscribing?

[malcolmmm] 09/5/2021 07:25

Happy now,👣

[12toes] 09/5/2021 03:52

Please don't ask to have a vote to have me back on the other board because I've got too much self respect and integrity to sate a board with a bunch of petulant uneducated immature kids

[12toes] 09/5/2021 03:49

You've written that nonsense 3 times now If you can't be bothered to correct your spelling error then don't post in our board bozo

[lukehold] 08/5/2021 23:13

Can we have a vote to get Pierre back!

[malcolmmm] 08/5/2021 21:37

Techinvest,Keep buying and they think that its a good thing to spin off IP assets to development separately from the core service business to secure separate financial resources for the accelerated development of these assets which will allow shareholders to benefit from both the value of the development assets and the standalone value of the core service business etc etc They explain why the demerger makes good financial sense and why it should happen.

[malcolmmm] 08/5/2021 21:35

Techinvest,Keep buying and they gave good reasons why